Back

Effects of intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction (IRON-HFpEF): a comprehensive multicenter phase 2 randomized clinical trial

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Diuretics and intravenous iron and more Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mr Soufiane Nassiri

Amsterdam (Netherlands (The))

2 More presentations in this session

Presentation thumbnail
Medical treatment implementation in ambulatory patients with HF: preliminary data from the nationwide BRING-UP3 HF study
Doctor E. D'Elia (Bergamo, IT)
Abstract Slides Video
Presentation thumbnail
Withdrawal of neurohumoral blockade in patients with normalized ejection fractions after cardiac resynchronization therapy: long-term follow-up of the STOP-CRT trial
Doctor M. Van Es (Genk, BE)
Abstract Slides Video

Access the full session

Session thumbnail
Diuretics and intravenous iron and more

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
PREFER­HF: Effects intravenous iron or oral iron therapy compared to placebo in HFpEF with iron deficiency anemia
thumbnail
Congress Presentation
Incorporating iron therapy in heart failure management across the ejection fraction spectrum
thumbnail
Congress Presentation
Iron deficiency in heart failure is associated with worse outcomes across the LVEF spectrum: the role of serum iron in HFpEF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources